Alexandria Real Estate (ARE) Q3 2026 Earnings Call Transcript

Alexandria Real Estate reported Q3 adjusted FFO of $1.54 per diluted share, down from $2.22 a year earlier, and a $3.74 diluted net loss largely reflecting $637.9 million of real estate impairments. Leasing reached 1.2 million RSF, while occupancy rose 20 bps sequentially to 87.1%; same-property NOI fell 6.7% year over year. Management maintained 2026 adjusted FFO guidance at a $6.40 midpoint and expects first-half 2027 occupancy pressure and negative same-property NOI in 2027, while targeting year-end net debt to adjusted EBITDA of 5.6x–6.2x.

Analysis

The key distinction is between leasing momentum and cash-flow recovery: much of the new space is not expected to commence until around mid-2027, while management still expects negative same-property NOI in 2027. That leaves ARE exposed to a lag in converting signed leases into occupancy and rent, with lease expirations and biotech tenant failures capable of extending the trough. The 2028 recovery case therefore depends on sustained vacant-space leasing—not simply this quarter’s volume.

The balance-sheet plan buys time but is not costless. Asset sales and partial-interest transactions can reduce leverage while preserving control, yet the JV structure’s distribution preference and put feature create future economic claims that headline proceeds do not capture. Further impairments would also signal that carrying values remain ahead of realizable prices, even if noncash. The Dec. 2 Investor Day is the next meaningful catalyst for testing 2027 spending, funding mix, and recovery assumptions.

A counterpoint to the bearish lab-supply narrative: advanced-technology tenants may absorb some well-located space with less landlord-funded conversion work, broadening demand beyond clinical biotech. That is a selective asset-level offset, not yet evidence of a portfolio-wide rent recovery. Overall, strong leasing is encouraging but not enough to establish a near-term earnings inflection.

Key Decisions for Investors

• Favor a cautious relative underweight in ARE versus a diversified REIT basket such as VNQ; avoid an outright short absent valuation and borrow-cost context. Reassess after the Dec. 2 Investor Day and subsequent occupancy/NOI updates.
• Treat executed leases as a leading indicator, not current cash-flow protection. Track commencement timing, operating occupancy, same-property cash NOI, and leasing of previously vacant space; deterioration in any of these would weaken the 2028 recovery thesis.
• Monitor disposition closings and JV terms alongside net debt/EBITDA. If sales slip, leverage misses the stated year-end range, or additional impairments emerge, downside risk rises; if proceeds close and occupancy converts on schedule, reduce the underweight.
• Do not extrapolate this quarter’s leasing into broad biotech demand. A sustained improvement in public-biotech funding and tenant activity would be a catalyst; continued weak clinical-stage financing or rising tenant wind-downs would falsify the stabilization case.